Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (MPDMDSBMT)
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes
About this trial
This is an interventional treatment trial for Chronic Myeloproliferative Disorders focused on measuring polycythemia vera, essential thrombocythemia, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, primary myelofibrosis, chronic myelogenous leukemia, adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), childhood myelodysplastic syndromes
Eligibility Criteria
INCLUSION CRITERIA: Myelodysplastic syndrome with IPSS score > 0.(Appendix B) Or Myeloproliferative disorders Primary Myelofibrosis with Lile score of 1 or 2 (Appendix C) Polycythemia Vera or Essential Thrombocythemia transformed to AML or Myelofibrosis and PV "spent phase" or Acute myelogenous leukemia or Chronic myelogenous leukemia Available Healthy Donor without any contraindications for donation. 5/6 or 6/6 related donor or 5/6 or 6/6 unrelated donor (molecular typing for DRB1) Able to give informed consent EXCLUSION CRITERIA: Patient is pregnant or lactating or unwilling to use contraceptives. HIV positive patient Uncontrolled intercurrent infection Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater) Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater) Hemodialysis dependent. Active hepatitis or cirrhosis with total bilirubin, SGOT, and SGPT greater than 3 x normal. Concurrent solid organ malignancy not in remission, except for Stage 0 or A prostate cancer. Unstable cerebral vascular disease or recent hemorrhagic stroke (less than 6 months) Active CNS disease from hematological disorder.
Sites / Locations
- Texas Children's Hospital
- The Methodist Hospital
Arms of the Study
Arm 1
Experimental
Submyeloablative Allogeneic Stem Cell Transplant
Total Body Irradiation Fludarabine Campath 1H